Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 23;12(11):1208.
doi: 10.3390/v12111208.

Evaluation of Commercially Available Viral Transport Medium (VTM) for SARS-CoV-2 Inactivation and Use in Point-of-Care (POC) Testing

Affiliations

Evaluation of Commercially Available Viral Transport Medium (VTM) for SARS-CoV-2 Inactivation and Use in Point-of-Care (POC) Testing

David van Bockel et al. Viruses. .

Abstract

Critical to facilitating SARS-CoV-2 point-of-care (POC) testing is assurance that viruses present in specimens are inactivated onsite prior to processing. Here, we conducted experiments to determine the virucidal activity of commercially available Viral Transport Mediums (VTMs) to inactivate SARS-CoV-2. Independent testing methods for viral inactivation testing were applied, including a previously described World Health Organization (WHO) protocol, in addition to a buffer exchange method where the virus is physically separated from the VTM post exposure. The latter method enables sensitive detection of viral viability at higher viral titre when incubated with VTM. We demonstrate that VTM formulations, Primestore® Molecular Transport Medium (MTM) and COPAN eNAT™ completely inactivate high-titre SARS-CoV-2 virus (>1 × 107 copies/mL) and are compatible with POC processing. Furthermore, full viral inactivation was rapidly achieved in as little as 2 min of VTM exposure. We conclude that adding certain VTM formulations as a first step post specimen collection will render SARS-CoV-2 non-infectious for transport, or for further in-field POC molecular testing using rapid turnaround GeneXpert platforms or equivalent.

Keywords: SARS-CoV-2; diagnostic; inactivation; virucidal.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Normalized viable cell count (per 1000) at Day 5 of culture following neutralization of SARS-CoV-2 in viral transport media at serial dilution. Count of viable Vero E6 cells is using NucBlue stain (normalized to a count of 1000 cells), when using the WHO method at low viral load (A,B), and high viral load (CE), diluted in 10-fold series. Viable cell count at Day 5 culture following neutralization and recovery of SARS-CoV-2 using the BEx method is indicated at low viral load (FH), and high viral load (IK), diluted in five-fold series. Incubation in media is indicated by colour (grey hexagon: negative control; red square/triangle(up)/triangle (down): positive [control(triplicate)], circle (pink): Primestore® MTM, (purple) COPAN™ eNAT, (blue) Qiagen AVL, square (khaki) COPAN™ UTM, (maroon) HCY-CV-19UTM, diamond (green) Sterigene®, diamond (gold) heat-inactivation). Incubation in media only for the WHO method is indicated by the dotted line connecting data points. Significant differences in median cell count (of quadruplicate measurements) above cell counts observed for control wells positive for SARS-CoV-2 are represented by asterisks corresponding to the colour of each medium at each point of serial dilution (faded asterisks indicate incubation in media alone; ND, test not done).

References

    1. Druce J., Garcia K., Tran T., Papadakis G., Birch C. Evaluation of Swabs, Transport Media, and Specimen Transport Conditions for Optimal Detection of Viruses by PCR. J. Clin. Microbiol. 2012;50:1064–1065. doi: 10.1128/JCM.06551-11. - DOI - PMC - PubMed
    1. Dunn J.J., Billetdeaux E., Skodack-Jones L., Carroll K.C. Evaluation of three Copan viral transport systems for the recovery of cultivatable, clinical virus isolates. Diagn. Microbiol. Infect. Dis. 2003;45:191–197. doi: 10.1016/S0732-8893(02)00541-2. - DOI - PubMed
    1. Moran A., Beavis K.G., Matushek S.M., Ciaglia C., Francois N., Tesic V., Love N. Detection of SARS-CoV-2 by Use of the Cepheid Xpert® Xpress SARS-CoV-2 and Roche Cobas SARS-CoV-2 Assays. J. Clin. Microbiol. 2020;58 doi: 10.1128/JCM.00772-20. - DOI - PMC - PubMed
    1. Moyo S., Mohammed T., Wirth K.E., Prague M., Bennett K., Holme M.P., Mupfumi L., Sebogodi P., Moraka N.O., Boleo C., et al. Point-of-Care Cepheid Xpert® HIV-1 Viral Load Test in Rural African Communities Is Feasible and Reliable. J. Clin. Microbiol. 2016;54:3050–3055. doi: 10.1128/JCM.01594-16. - DOI - PMC - PubMed
    1. Cohen D.M., Kline J., May L.S., Harnett G.E., Gibson J., Liang S.Y., Rafique Z., Rodriguez C.A., McGann K.M., Gaydos C.A., et al. Accurate PCR Detection of Influenza A/B and Respiratory Syncytial Viruses by Use of Cepheid Xpert® Flu+RSV Xpress Assay in Point-of-Care Settings: Comparison to Prodesse ProFlu+ J. Clin. Microbiol. 2017;56 doi: 10.1128/JCM.01237-17. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources